Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of SHR0302 Oral Solution vs Tablet in Healthy Subjects
NCT05856058Phase 1Completed
- Sponsor
- Hengrui
- Start
- May 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ivarmacitinib in graft-versus-host disease (GVHD) (2 arms), sponsored by Hengrui. Primary endpoints: Area Under the Curve from time 0 to time t, Area Under the Curve from time 0 to infinity and 2 more. Started May 2023; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05856058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05856058.